Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0533
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy ; volume:133 ; number:1 ; day:29 ; month:11 ; year:2016 ; pages:149-151 ; date:1.2017
Acta neuropathologica ; 133, Heft 1 (29.11.2016), 149-151, 1.2017
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Urheber
-
Smith, Ruben
- Beteiligte Personen und Organisationen
-
Schöll, Michael
Honer, Michael
Nilsson, Christer F.
Englund, Elisabet
Hansson, Oskar
SpringerLink (Online service)
- DOI
-
10.1007/s00401-016-1650-1
- URN
-
urn:nbn:de:1111-201701306399
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Smith, Ruben
- Schöll, Michael
- Honer, Michael
- Nilsson, Christer F.
- Englund, Elisabet
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
![[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case](/assets/placeholder/searchResultMediaUnknown.png)
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
FDG-PET AND PET/CT-Part I
FDG-PET in lymphoma
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
FDG-PET in juvenile systemic lupus erythematosus
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
Treffsicherheit der FDG-PET beim Lymphknotenstaging des Bronchialkarzinoms
FDG-PET findings of Ameloblastoma: a case report
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
FDG-PET AND PET/CT-Part I
FDG-PET in lymphoma
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
FDG-PET in juvenile systemic lupus erythematosus
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
Treffsicherheit der FDG-PET beim Lymphknotenstaging des Bronchialkarzinoms
FDG-PET findings of Ameloblastoma: a case report
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
FDG-PET AND PET/CT-Part I
FDG-PET in lymphoma
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
FDG-PET in juvenile systemic lupus erythematosus
Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism
Treffsicherheit der FDG-PET beim Lymphknotenstaging des Bronchialkarzinoms